EVLO.US Evelo Biosciences Inc

Healthcare Biotechnology USA Stocks
0.0001 USD
Close of Nov 13, 2026
0.0001 0.0005
Market cap
USD 1.90K
P/E
-
P/B
3.51x
ROE
-
Dividend yield
-
Fundamental score
-

Is EVLO.US undervalued?

Graham number

The Graham number of Evelo Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Evelo Biosciences Inc fundamental analysis

No fundamental analysis for Evelo Biosciences Inc yet.

Evelo Biosciences Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Evelo Biosciences Inc

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriasis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2…

Full company profile